Report cover image

mRNA Vaccine and Therapeutics Market, By Product Type (mRNA Vaccines, mRNA Therapeutics); By Route of Administration (Intramuscular, Intravenous, Others); By Application (Cancer, Genetic Disorders, Infectious Diseases, Cardiovascular Disorders, Others); B

Publisher BlueWeave Consulting
Published Jul 07, 2025
Length 499 Pages
SKU # BLWC20227914

Description

Global mRNA Vaccine and Therapeutics Market Zooming 2.7X to Cross USD 36 Billion by 2031
Global mRNA Vaccine and Therapeutics Market is flourishing because of an escalating demand for gene and cell therapies, an increasing number of regulatory approvals for viral vector-based drugs and vaccines, and the rising volume of clinical trials in the innovative therapeutic space.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated Global mRNA Vaccine and Therapeutics Market size at USD 13.36 billion in 2024. During the forecast period between 2025 and 2031, BlueWeave expects Global mRNA Vaccine and Therapeutics Market size to boom at a robust CAGR of 15.5% reaching a value of USD 36.64 Billion by 2031. The growth of mRNA Vaccine and Therapeutics Market across the regions is propelled by an increasing focus on mRNA-based treatments for chronic diseases. These lab-generated therapeutics offer enhanced safety, production efficiency, and superior immunological advantages over traditional DNA vaccines by triggering robust B- and T-cell immune responses through viral antigen production. The urgent global demand for effective COVID-19 vaccines greatly accelerated mRNA research and development, prompting pharmaceutical companies to prioritize these solutions. Furthermore, the emergence of new viral strains has led regulatory authorities to fast-track approvals via emergency and conditional authorizations, further fueling market expansion.

Impact of Escalating Geopolitical Tensions on Global mRNA Vaccine and Therapeutics Market

Intensifying geopolitical tensions could disrupt the growth of Global mRNA Vaccine and Therapeutics Market. Such conflicts invariably disrupt global supply chains, jeopardizing the timely availability of crucial raw materials and specialized components essential for mRNA vaccine production. Trade restrictions, sanctions, and border closures can lead to considerable delays in manufacturing timelines and drive up production costs, impacting affordability and accessibility. Furthermore, political instability often results in a reallocation of government funding, potentially diverting resources away from vital healthcare innovation, thereby impeding research and development efforts in the mRNA space. The inherent uncertainty in international relations can also hinder global collaborations and regulatory harmonization, both of which are critical for the efficient conduct of clinical trials and the equitable distribution of these life-saving therapeutics. Collectively, these multifaceted challenges present substantial risks to the market's anticipated expansion and global accessibility.

North America Leads Global mRNA Vaccine and Therapeutics Market

North America currently holds and is expected to maintain the largest share in the Global mRNA Vaccine and Therapeutics Market. The dominance is largely driven by strong contributions from United States and Canada, with United States at the forefront due to substantial funding for mRNA vaccine development, a robust pipeline of therapeutic candidates, and the significant presence of both established and emerging pharmaceutical companies. The region benefits from advanced manufacturing infrastructure, including sophisticated ultracold supply chains, and increasing public awareness of mRNA technologies. Key industry players like Moderna and strategic partnerships, such as with Catalent for large-scale production, have further solidified the regional market. Additionally, investments from organizations like CEPI and active involvement of companies such as Translate Bio and Arcturus Therapeutics are fueling continued growth, ensuring North America's sustained leadership in the Global mRNA Vaccine and Therapeutics Market.
Competitive Landscape
Major companies in Global mRNA Vaccine and Therapeutics Market include Sanofi, GSK Plc., AstraZeneca, CureVac N.V., Moderna Inc., Arcturus Therapeutics, BioNTech SE, Pfizer Inc., Daiichi Sankyo Company, Silence Therapeutics, Ethris GmbH, Panthera Therapeutics GmbH, Argos Therapeutics Inc., Gennova Biopharmaceuticals Ltd, and Providence Therapeutics. The presence of high number of companies intensify the market competition as they compete to gain a significant market share. These companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches to further enhance their market share.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and Global mRNA Vaccine and Therapeutics Market statistics. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global mRNA Vaccine and Therapeutics Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

499 Pages
1. Research Framework
1.1. Research Objective
1.2. mRNA Vaccine and Therapeutics Market Overview
1.3. Market Segmentation
2. Executive Summary
3. Global mRNA Vaccine and Therapeutics Market Insights
3.1. End User Value Chain Analysis
3.2. DROC Analysis
3.2.1. Growth Drivers
3.2.1.1. Growing Demand for Personalized Medicine & Precision Therapies
3.2.1.2. Rising Adoption of mRNA Technology
3.2.1.3. Increasing Government Investments & Public-Private Partnerships
3.2.2. Restraints
3.2.2.1. Rising Production Costs
3.2.2.2. Increasing Dependency on Cold Chain Logistics
3.2.3. Opportunities
3.2.3.1. Advancements in AI & Synthetic Biology
3.2.3.2. Growing Application of mRNA in Cancer Immunotherapy & Genetic Disease Treatment
3.2.4. Challenges
3.2.4.1. Increasing Competition from Alternative Vaccines
3.2.4.2. Regulatory Uncertainty
3.3. Technological Advancements/Recent Developments
3.4. Regulatory Framework
3.5. Porter’s Five Forces Analysis
3.5.1. Bargaining Power of Suppliers
3.5.2. Bargaining Power of Buyers
3.5.3. Threat of New Entrants
3.5.4. Threat of Substitutes
3.5.5. Intensity of Rivalry
4. Global mRNA Vaccine and Therapeutics Market: Marketing Strategies
5. Global mRNA Vaccine and Therapeutics Market: Pricing Analysis
6. Global mRNA Vaccine and Therapeutics Market: Geography Analysis
6.1. Global mRNA Vaccine and Therapeutics Market, Geographical Analysis, 2024
6.2. Global mRNA Vaccine and Therapeutics, Market Attractiveness Analysis, 2024–2031
7. Global mRNA Vaccine and Therapeutics Market Overview
7.1. Market Size & Forecast, 2019–2031
7.1.1. By Value (USD Billion)
7.2. Market Share & Forecast
7.2.1. By Product Type
7.2.1.1. mRNA Vaccines
7.2.1.2. mRNA Therapeutics
7.2.2. By Route of Administration
7.2.2.1. Intramuscular
7.2.2.2. Intravenous
7.2.2.3. Others
7.2.3. By Application
7.2.3.1. Cancer
7.2.3.2. Genetic Disorders
7.2.3.3. Infectious Diseases
7.2.3.4. Cardiovascular Disorders
7.2.3.5. Others
7.2.4. By End User
7.2.4.1. Hospitals & Clinics
7.2.4.2. Research Organizations
7.2.4.3. Pharmaceutical & Biotechnology Companies
7.2.4.4. Others
7.2.5. By Region
7.2.5.1. North America
7.2.5.2. Europe
7.2.5.3. Asia Pacific
7.2.5.4. Latin America
7.2.5.5. Middle East and Africa
8. North America mRNA Vaccine and Therapeutics Market
8.1. Market Size & Forecast, 2019–2031
8.1.1. By Value (USD Billion)
8.2. Market Share & Forecast
8.2.1. By Product Type
8.2.2. By Route of Administration
8.2.3. By Application
8.2.4. By End User
8.2.5. By Country
8.2.5.1. United States
8.2.5.1.1. By Product Type
8.2.5.1.2. By Route of Administration
8.2.5.1.3. By Application
8.2.5.1.4. By End User
8.2.5.2. Canada
8.2.5.2.1. By Product Type
8.2.5.2.2. By Route of Administration
8.2.5.2.3. By Application
8.2.5.2.4. By End User
9. Europe mRNA Vaccine and Therapeutics Market
9.1. Market Size & Forecast, 2019–2031
9.1.1. By Value (USD Billion)
9.2. Market Share & Forecast
9.2.1. By Product Type
9.2.2. By Route of Administration
9.2.3. By Application
9.2.4. By End User
9.2.5. By Country
9.2.5.1. Germany
9.2.5.1.1. By Product Type
9.2.5.1.2. By Route of Administration
9.2.5.1.3. By Application
9.2.5.1.4. By End User
9.2.5.2. United Kingdom
9.2.5.2.1. By Product Type
9.2.5.2.2. By Route of Administration
9.2.5.2.3. By Application
9.2.5.2.4. By End User
9.2.5.3. Italy
9.2.5.3.1. By Product Type
9.2.5.3.2. By Route of Administration
9.2.5.3.3. By Application
9.2.5.3.4. By End User
9.2.5.4. France
9.2.5.4.1. By Product Type
9.2.5.4.2. By Route of Administration
9.2.5.4.3. By Application
9.2.5.4.4. By End User
9.2.5.5. Spain
9.2.5.5.1. By Product Type
9.2.5.5.2. By Route of Administration
9.2.5.5.3. By Application
9.2.5.5.4. By End User
9.2.5.6. Belgium
9.2.5.6.1. By Product Type
9.2.5.6.2. By Route of Administration
9.2.5.6.3. By Application
9.2.5.6.4. By End User
9.2.5.7. Russia
9.2.5.7.1. By Product Type
9.2.5.7.2. By Route of Administration
9.2.5.7.3. By Application
9.2.5.7.4. By End User
9.2.5.8. The Netherlands
9.2.5.8.1. By Product Type
9.2.5.8.2. By Route of Administration
9.2.5.8.3. By Application
9.2.5.8.4. By End User
9.2.5.9. Rest of Europe
9.2.5.9.1. By Product Type
9.2.5.9.2. By Route of Administration
9.2.5.9.3. By Application
9.2.5.9.4. By End User
10. Asia Pacific mRNA Vaccine and Therapeutics Market
10.1. Market Size & Forecast, 2019–2031
10.1.1. By Value (USD Billion)
10.2. Market Share & Forecast
10.2.1. By Product Type
10.2.2. By Route of Administration
10.2.3. By Application
10.2.4. By End User
10.2.5. By Country
10.2.5.1. China
10.2.5.1.1. By Product Type
10.2.5.1.2. By Route of Administration
10.2.5.1.3. By Application
10.2.5.1.4. By End User
10.2.5.2. India
10.2.5.2.1. By Product Type
10.2.5.2.2. By Route of Administration
10.2.5.2.3. By Application
10.2.5.2.4. By End User
10.2.5.3. Japan
10.2.5.3.1. By Product Type
10.2.5.3.2. By Route of Administration
10.2.5.3.3. By Application
10.2.5.3.4. By End User
10.2.5.4. South Korea
10.2.5.4.1. By Product Type
10.2.5.4.2. By Route of Administration
10.2.5.4.3. By Application
10.2.5.4.4. By End User
10.2.5.5. Australia & New Zealand
10.2.5.5.1. By Product Type
10.2.5.5.2. By Route of Administration
10.2.5.5.3. By Application
10.2.5.5.4. By End User
10.2.5.6. Indonesia
10.2.5.6.1. By Product Type
10.2.5.6.2. By Route of Administration
10.2.5.6.3. By Application
10.2.5.6.4. By End User
10.2.5.7. Malaysia
10.2.5.7.1. By Product Type
10.2.5.7.2. By Route of Administration
10.2.5.7.3. By Application
10.2.5.7.4. By End User
10.2.5.8. Singapore
10.2.5.8.1. By Product Type
10.2.5.8.2. By Route of Administration
10.2.5.8.3. By Application
10.2.5.8.4. By End User
10.2.5.9. Vietnam
10.2.5.9.1. By Product Type
10.2.5.9.2. By Route of Administration
10.2.5.9.3. By Application
10.2.5.9.4. By End User
10.2.5.10. Rest of APAC
10.2.5.10.1. By Product Type
10.2.5.10.2. By Route of Administration
10.2.5.10.3. By Application
10.2.5.10.4. By End User
11. Latin America mRNA Vaccine and Therapeutics Market
11.1. Market Size & Forecast, 2019–2031
11.1.1. By Value (USD Billion)
11.2. Market Share & Forecast
11.2.1. By Product Type
11.2.2. By Route of Administration
11.2.3. By Application
11.2.4. By End User
11.2.5. By Country
11.2.5.1. Brazil
11.2.5.1.1. By Product Type
11.2.5.1.2. By Route of Administration
11.2.5.1.3. By Application
11.2.5.1.4. By End User
11.2.5.2. Mexico
11.2.5.2.1. By Product Type
11.2.5.2.2. By Route of Administration
11.2.5.2.3. By Application
11.2.5.2.4. By End User
11.2.5.3. Argentina
11.2.5.3.1. By Product Type
11.2.5.3.2. By Route of Administration
11.2.5.3.3. By Application
11.2.5.3.4. By End User
11.2.5.4. Peru
11.2.5.4.1. By Product Type
11.2.5.4.2. By Route of Administration
11.2.5.4.3. By Application
11.2.5.4.4. By End User
11.2.5.5. Rest of LATAM
11.2.5.5.1. By Product Type
11.2.5.5.2. By Route of Administration
11.2.5.5.3. By Application
11.2.5.5.4. By End User
12. Middle East & Africa mRNA Vaccine and Therapeutics Market
12.1. Market Size & Forecast, 2019–2031
12.1.1. By Value (USD Billion)
12.2. Market Share & Forecast
12.2.1. By Product Type
12.2.2. By Route of Administration
12.2.3. By Application
12.2.4. By End User
12.2.5. By Country
12.2.5.1. Saudi Arabia
12.2.5.1.1. By Product Type
12.2.5.1.2. By Route of Administration
12.2.5.1.3. By Application
12.2.5.1.4. By End User
12.2.5.2. UAE
12.2.5.2.1. By Product Type
12.2.5.2.2. By Route of Administration
12.2.5.2.3. By Application
12.2.5.2.4. By End User
12.2.5.3. Qatar
12.2.5.3.1. By Product Type
12.2.5.3.2. By Route of Administration
12.2.5.3.3. By Application
12.2.5.3.4. By End User
12.2.5.4. Kuwait
12.2.5.4.1. By Product Type
12.2.5.4.2. By Route of Administration
12.2.5.4.3. By Application
12.2.5.4.4. By End User
12.2.5.5. South Africa
12.2.5.5.1. By Product Type
12.2.5.5.2. By Route of Administration
12.2.5.5.3. By Application
12.2.5.5.4. By End User
12.2.5.6. Nigeria
12.2.5.6.1. By Product Type
12.2.5.6.2. By Route of Administration
12.2.5.6.3. By Application
12.2.5.6.4. By End User
12.2.5.7. Algeria
12.2.5.7.1. By Product Type
12.2.5.7.2. By Route of Administration
12.2.5.7.3. By Application
12.2.5.7.4. By End User
12.2.5.8. Rest of MEA
12.2.5.8.1. By Product Type
12.2.5.8.2. By Route of Administration
12.2.5.8.3. By Application
12.2.5.8.4. By End User
13. Competitive Landscape
13.1. List of Key Players and Their Types
13.2. Global mRNA Vaccine and Therapeutics Company Market Share Analysis, 2024
13.3. Competitive Benchmarking, By Operating Parameters
13.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)
14. Impact of Escalating Geopolitical Tensions on Global mRNA Vaccine and Therapeutics Market
15. Company Profiles (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)
15.1. Sanofi
15.2. GSK Plc
15.3. AstraZeneca
15.4. CureVac N.V.
15.5. Moderna Inc.
15.6. Arcturus Therapeutics
15.7. BioNTech SE
15.8. Pfizer Inc.
15.9. Daiichi Sankyo Company
15.10. Silence Therapeutics
15.11. Ethris GmbH
15.12. Panthera Therapeutics GmbH
15.13. Argos Therapeutics Inc.
15.14. Gennova Biopharmaceuticals Ltd
15.15. Providence Therapeutics
15.16. Other Prominent Players
16. Key Strategic Recommendations
17. Research Methodology
17.1. Qualitative Research
17.1.1. Primary & Secondary Research
17.2. Quantitative Research
17.3. Market Breakdown & Data Triangulation
17.3.1. Secondary Research
17.3.2. Primary Research
17.4. Breakdown of Primary Research Respondents, By Region
17.5. Assumptions & Limitations
*Financial information of non-listed companies can be provided as per availability.
**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us